<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762888</url>
  </required_header>
  <id_info>
    <org_study_id>20-006433</org_study_id>
    <secondary_id>NCI-2021-01092</secondary_id>
    <secondary_id>20-006433</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT04762888</nct_id>
  </id_info>
  <brief_title>68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer</brief_title>
  <official_title>Early Detection, Accurate Staging, and Biologic Characterization of HCC With Hybrid 68Ga-PSMA-Dual -Contrast PET/MRI and PET/CT Using Cyclotron-Produced 68Ga</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well 68Ga-PSMA PET/MRI or PET/CT works in early detection of&#xD;
      liver cancer. 68Gallium-PSMA is a radioactive tracer designed to circulate through the body&#xD;
      and attach itself to the prostate- specific membrane antigen (PSMA) protein on liver cancer&#xD;
      cells. Magnetic resonance imaging (MRI) is a scan that uses magnetic and radio waves to&#xD;
      produce detailed structural information of the organs, tissues, and structures within the&#xD;
      body. Positron emission tomography (PET) is an imaging test that helps to measure the&#xD;
      information about functions of tissues and organs within the body. A PET scan uses a&#xD;
      radioactive drug (tracer) to show this activity. Computed tomography (CT) scan uses X-rays to&#xD;
      create images of the bones and internal organs within your body. Combining a PET scan with an&#xD;
      MRI or CT scan may help make the images easier to interpret. This trial may help determine if&#xD;
      68Ga- PSMA PET/MRI or PET/CT can improve upon the diagnosis and management of liver cancer in&#xD;
      the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the feasibility and diagnostic performance of gallium Ga 68 gozetotide (68Ga&#xD;
      PSMA)-dual contrast PET/MRI for detection and staging of hepatocellular carcinoma (HCC), and&#xD;
      to compare it with standard-of-care (SOC) imaging.&#xD;
&#xD;
      II. To identify the biologic correlates of biomarkers derived from 68Ga PSMA-dual contrast&#xD;
      PET/MRI with histopathology features and PSMA immunostaining of HCC.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive 68Ga-PSMA intravenously (IV) over 90 minutes. Patients then undergo PET/MRI&#xD;
      over 60 minutes or PET/CT over 30 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2021</start_date>
  <completion_date type="Anticipated">February 4, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 4, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance of 68Ga-PSMA-dual contrast</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Using surgical histopathology of resected or biopsied lesions and routine imaging surveillance (for lesions that cannot be resected or biopsied) as the gold standard, we will estimate the diagnostic performance (lesion-level sensitivity, specificity measures, and corresponding 95% confidence intervals) of PET/MRI for hepatic lesions and extra-hepatic metastases, and compare it with standard-of-care (SOC) imaging (MRI and CT) to identify the incremental benefit of PET/MRI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate biomarkers derived from PET/MRI with PSMA immuno-histochemical (IHC) grading</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>PSMA stained sections will be evaluated by light microscopy for PSMA localization and the entire section reviewed to determine percentage area of PSMA immunostaining as follows: 0 = no staining, 1 = &lt; 5% staining, 2= 5 to 30% staining, 3 = 31 to 60% staining, and 4 = 61-100% staining. Grades 0-2 will be grouped as 'low PSMA expression' and grades 3 and 4 will be grouped as 'high PSMA expression'</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate biomarkers derived from PET/MRI with PSMA immuno-histochemical (IHC) grading</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>Intensity of PSMA uptake in hepatic lesions on PET will be graded as follows: grade 1: uptake &lt; normal liver; grade 2: uptake = normal liver; grade 3: uptake &gt; normal liver; grade 4: uptake &gt; spleen or kidneys. For correlation with PSMA IHC scoring, grades 1 and 2 on PET/MRI will be grouped as 'low PSMA expression'. Conversely, grades 3 and 4 will be grouped as 'high PSMA expression'.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (68Ga-PSMA PET/MRI or PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 68Ga-PSMA IV over 90 minutes. Patients then undergo PET/MRI over 60 minutes or PET/CT over 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Diagnostic (68Ga-PSMA PET/MRI or PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium Ga 68 Gozetotide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (68Ga-PSMA PET/MRI or PET/CT)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68Ga)Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-DKFZ-PSMA-11</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>68Ga-PSMA-HBED-CC</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga PSMA</other_name>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>GA-68 PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium Ga 68-labeled PSMA-11</other_name>
    <other_name>GALLIUM GA-68 GOZETOTIDE</other_name>
    <other_name>Gallium-68 PSMA</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>GaPSMA</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo PET/MRI</description>
    <arm_group_label>Diagnostic (68Ga-PSMA PET/MRI or PET/CT)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MR Imaging</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>PET/MRI or PET/CT</description>
    <arm_group_label>Diagnostic (68Ga-PSMA PET/MRI or PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with either an imaging diagnosis of HCC by CT or MRI (Liver Imaging Reporting&#xD;
             and Data System [LI-RADS] 5) confirmed by a board-certified abdominal radiologist, or&#xD;
             with biopsy-proven HCC&#xD;
&#xD;
          -  No prior treatment for HCC&#xD;
&#xD;
          -  Patients who may undergo hepatic surgical resection or liver transplant&#xD;
&#xD;
          -  Male or female with age greater than 18 years, with the capacity and willingness to&#xD;
             provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients requiring emergent surgery for a ruptured/bleeding HCC&#xD;
&#xD;
          -  Bilirubin &gt; 3.0 mg/dL, which is a contraindication for Gadoxetate, the MRI contrast&#xD;
             agent (relevant to PET/MRI)&#xD;
&#xD;
          -  Patients with glomerular filtration rate (GFR) &lt; 30 ml/min/1.73m^2, on dialysis, or&#xD;
             with acute kidney injury&#xD;
&#xD;
          -  Pregnant and/or breast-feeding patients. A negative pregnancy test within 48 hours of&#xD;
             the PET scan&#xD;
&#xD;
          -  Patients with higher than the weight/size limitations of PET/MRI or PET/CT scanner&#xD;
&#xD;
          -  Subjects with history of allergic response to Eovist or Gadavist&#xD;
&#xD;
          -  Subjects with known history of claustrophobia&#xD;
&#xD;
          -  Subjects with GFR &lt; 30 ml/min/1.73m^2, on dialysis, or with acute kidney injury&#xD;
&#xD;
          -  Subjects with a history of severe hypersensitivity to Eovist or Gadavist&#xD;
&#xD;
          -  Patients with contraindication to MRI (relevant to PET/MRI):&#xD;
&#xD;
               -  Patients who have a heart pacemaker&#xD;
&#xD;
               -  Patients who have a metallic foreign body (metal sliver) in their eye, or who&#xD;
                  have an aneurysm clip in their brain&#xD;
&#xD;
               -  Patients who have implanted devices with magnets&#xD;
&#xD;
               -  Patients who have other implanted electronic devices&#xD;
&#xD;
               -  Patients who have deep brain stimulator&#xD;
&#xD;
               -  Patients who have vagal nerve stimulator&#xD;
&#xD;
               -  Patients with cochlear (ear) or auditory implants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajit H Goenka</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic in Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
      <email>mayocliniccancerstudies@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Ajit H. Goenka, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

